Pharmaceuticals, Free Full-Text

$ 25.00

5 (87) In stock

Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has not developed BBB drug delivery technology, which would enable industry to invent new therapeutics for AD that actually penetrate into brain parenchyma from blood. In 2020, less than 1% of all AD drug development projects use a BBB drug delivery technology. The pathogenesis of AD involves chronic neuro-inflammation, the progressive deposition of insoluble amyloid-beta or tau aggregates, and neural degeneration. New drugs that both attack these multiple sites in AD, and that have been coupled with BBB drug delivery technology, can lead to new and effective treatments of this serious disorder.

Synergistic removal of pharmaceuticals and antibiotic resistance from ultrafiltered WWTP effluent: Free-floating ARGs exceptionally susceptible to degradation - ScienceDirect

Pharmaceuticals Free Full-Text Preclinical Efficacy And, 54% OFF

Pharmaceuticals, Free Full-Text

Pharmaceuticals, Free Full-Text

Online Pharmacy India Buy Medicines from India's Trusted Medicine Store

Solved Purple Panda Pharmaceuticals Inc.'s free cash flows

Pharmaceuticals, Free Full-Text

PDF) Pharmaceuticals, intellectual property and free trade: the case of the US-Australia Free Trade Agreement

Gestational - Diabetes In Pregnancy Causes, Symptoms and Diagnosis, Pregnancy Needs